PODD Stock Recent News

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Omnipod 5, compatible with both Dexcom G6 and Abbott FreeStyle Libre 2 Plus continuous glucose monitor (CGM) sensors, is now fully available in the U.K. and the Netherlands for individuals aged two years and older with type 1 diabetes. Omnipod 5 is the first and only tubeless automated insulin.

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today made several exciting announcements regarding the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), including its availability in France with Dexcom G6 compatibility, as well as two updates for the U.S. market — the commencement of the Omnipod 5 with Dexcom G7 integration full commercial launch as well.

The robust performance of Insulet's (PODD) Omnipod 5 raises investors' optimism. However, concerns remain over the macroeconomic impacts and the company's overdependence on a single platform.

Insulet Corporation saw a significant drop in stock price in 2023 due to concerns over the impact of GLP-1 weight loss drugs on the insulin pump industry. These fears seem to be largely overblown, however, meaning that Insulet is arguably still trading at a substantial discount to its true value as a company. Insulet's CEO believes that GLP-1 drugs are increasing the adoption of insulin, not decreasing it, suggesting a positive impact on the iCGM industry.

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the Jefferies Global Healthcare Conference in New York City on Thursday, June 6, 2024 at 9:00 a.m. (Eastern Time). To listen to the live audio webcast of the presentation, please visit investors.insulet.com/events. A replay of the webcast will also be available following the event.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Insulet's (PODD) first-quarter performance benefits from the continued high demand for Omnipod 5.

Insulet Corporation (NASDAQ:PODD ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Jim Hollingshead - President and Chief Executive Officer Ana Maria Chadwick - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Margaret Kaczor - William Blair Robbie Marcus - JP Morgan Jeff Johnson - Baird Michael Polark - Wolfe Research Travis Steed - Bank of America Larry Biegelsen - Wells Fargo Patrick Wood - Morgan Stanley Matt Taylor - Jefferies Jayson Bedford - Raymond James Steve Lichtman - Oppenheimer & Co. Joanne Wuensch - Citi Danielle Antalffy - UBS William Plovanic - Canaccord Genuity Marie Thibault - BTIG Chris Pasquale - Nephron Josh Jennings - TD Cowen Operator Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation First Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.

While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.